ArticleNoro psikiyatri arsivi2024
Meta-Analysis of the Efficacy of Risperidone Treatment in Patients with First-Episode Schizophrenia.
Article in Noro psikiyatri arsivi, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transition rates to schizophrenia and early intervention effectiveness in substance-induced and brief psychotic disorders: a randomized controlled trial.Scientific reports · 2025Trial
- Emerging Neurobiological and Therapeutic Insights into Schizophrenia: A Comprehensive Review.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: First-episode schizophrenia is a prevalent psychiatric disorder with a complex etiology. This meta-analysis evaluates the efficacy of risperidone in treating patients with first-episode schizophrenia. Methods: A literature search was conducted to identify studies on the efficacy of risperidone for first-episode schizophrenia. The literature was evaluated for quality, and a meta-analysis was then performed. Results: A total of 15 articles (6 in Chinese and 9 in English) were included. The meta-analysis revealed statistically significant differences in the cure rate (relative risk [RR]=0.51, 95% confidence interval [CI]: 0.46-0.57, p <0.001) and the total marked improvement rate (RR=0.58, 95% CI: 0.52-0.65, p <0.001) favoring risperidone over control groups. The incidence of weight gain (p <0.001) and extrapyramidal symptoms (p=0.005) was higher with risperidone. Conclusion: Risperidone shows increased cure and effective rates compared with control groups (including placebo and other antipsychotics) in the treatment of patients with first-episode schizophrenia. However, it may increase the risk of extrapyramidal reactions and weight gain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.